<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00289978</url>
  </required_header>
  <id_info>
    <org_study_id>CFTY720D2301</org_study_id>
    <nct_id>NCT00289978</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis</brief_title>
  <acronym>FREEDOMS</acronym>
  <official_title>A 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of Fingolimod 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study assessed the efficacy, safety, and tolerability of 2 doses of oral fingolimod
      (1.25 mg/day and 0.5 mg/day) compared to placebo in patients with relapsing-remitting
      multiple sclerosis (RRMS)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimated Annualized Aggregate Relapse Rate (ARR)</measure>
    <time_frame>Baseline to end of study (Month 24)</time_frame>
    <description>The ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group calculated as the total number of confirmed relapses divided by the total number of days on study, multiplied by 365.25.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Free of Disability Progression at Month 24 Assessed With the Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>Baseline to end of study (Month 24)</time_frame>
    <description>EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the following: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. A 3-month confirmed disability progression required onset EDSS, 3-month confirming EDSS, and all EDSS in between to meet the disability progression criteria. Percent of free of disability progression was calculated using the Kaplan Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of New or Newly Enlarged T2 Lesions at Month 24 in Comparison With Baseline</measure>
    <time_frame>Baseline to end of study (Month 24)</time_frame>
    <description>The number of new or newly enlarged T2 lesions at Month 24 in comparison to baseline was assessed with T2-weighted magnetic resonance image (MRI) scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2-weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1272</enrollment>
  <condition>Relapsing-remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Fingolimod 1.25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fingolimod 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fingolimod 1.25 mg</intervention_name>
    <description>Patients self-administered fingolimod 1.25 mg capsules orally once daily.</description>
    <arm_group_label>Fingolimod 1.25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fingolimod 0.5 mg</intervention_name>
    <description>Patients self-administered fingolimod 0.5 mg capsules orally once daily.</description>
    <arm_group_label>Fingolimod 0.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients self-administered a fingolimod placebo capsule orally once daily.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients between ages 18-55 with a diagnosis of multiple sclerosis

          -  Patients with a relapsing-remitting disease course

          -  Patients with EDSS score of 0-5.5

        Exclusion Criteria:

          -  Patients with other chronic disease of the immune system, malignancies, acute
             pulmonary disease, cardiac failure, etc.

          -  Pregnant or nursing women

        Other protocol-defined inclusion/exclusion criteria applied to this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Gosford Private Hospital</name>
      <address>
        <city>Burrabil Avenue, Suite 17, Gosford</city>
        <zip>NSW 2250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strategic Health Evaluators</name>
      <address>
        <city>Chatswood</city>
        <zip>2067</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Melbourne, Department of Clinical Neurosciences</name>
      <address>
        <city>Fitzroy</city>
        <zip>3065 VIC</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Health, Department of Neurology</name>
      <address>
        <city>Heidelberg</city>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis St. Jan, Department of Neurology</name>
      <address>
        <city>Ruddershove 10</city>
        <state>Brugge</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasme Hospital</name>
      <address>
        <city>Route de Lennik 808</city>
        <state>Brussels</state>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Charleroi, HÃ´pital Civil</name>
      <address>
        <city>Boulevard Paul Janson 92</city>
        <state>Charleroi</state>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Gasthuisberg</name>
      <address>
        <city>Department Neurology, Herestraat 49</city>
        <state>Leuven</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Alma</name>
      <address>
        <city>Department of Neurology &amp; Rehab-Umit, Gentsesteenweg 132</city>
        <state>Sijsele</state>
        <zip>8340</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionaal Ziekenhuis</name>
      <address>
        <city>St.Trudo, Diestersteenweg 100,</city>
        <state>St.Truiden</state>
        <zip>3800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MS Klinik</name>
      <address>
        <city>Boemerangstraat 2, Overpelt</city>
        <zip>3900</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Multiple Sclerose Centrum v.z.w</name>
      <address>
        <city>Vanheylenstraat 16, Melsbroek</city>
        <zip>1820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>ME498 2211 Wesbrook Mall, Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DMSRU - Capital Health</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital, MS Clinic</name>
      <address>
        <city>Connell 7, 76 Stuart Street, Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nepean Medical Center</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2G 6E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Office,</name>
      <address>
        <city>Trillium Health Center, 00 Queesway West, Mississauga</city>
        <state>Ontario</state>
        <zip>L5B 1B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve-Rosemont, Recherche Clinique de Neurologie</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Saskatchewan</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Hospital of Brno</name>
      <address>
        <city>Department of Neurology, Zabrdovicka 3</city>
        <state>Brno</state>
        <zip>63600</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital St. Anne</name>
      <address>
        <city>First Department of Neurology, Pekarska 53</city>
        <state>Brno</state>
        <zip>65691</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital</name>
      <address>
        <city>Department of Neurology, I.P. Paulova 6</city>
        <state>Olomouc</state>
        <zip>77520</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Pardubice</name>
      <address>
        <city>Department of Neurology, Kyjevska 44</city>
        <state>Pardubice</state>
        <zip>53203</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital</name>
      <address>
        <city>Department of Neurology, Alej Svobody 80</city>
        <state>PlzeÅ</state>
        <zip>3046</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital Motol, MS Center</name>
      <address>
        <city>Department of Neurology, V Uvalu 84</city>
        <state>Prague 5</state>
        <zip>15006</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice</name>
      <address>
        <city>MS Centrum, Neurologicka klinika, Karlovo namesti 32</city>
        <state>Praha 2</state>
        <zip>12808</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologicka klinika, Fakultni nemocnice</name>
      <address>
        <city>Kralovske Vinohrady, Srobarova 50</city>
        <state>Praha</state>
        <zip>10034</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MS Centrum</name>
      <address>
        <city>Neurology Department of Hospital Teplice, Duchcovska 53</city>
        <state>Teplice</state>
        <zip>41529</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum neurologicke pece</name>
      <address>
        <city>Jiraskova 1389, Rychnov nad Kneznou</city>
        <zip>51601</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FacultnÃ­ Nemocnice Spoliklinikou Ostrava, Neurology Department</name>
      <address>
        <city>Ostrava</city>
        <zip>70852</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki Headache Center Postitalon LÃ¤Ã¤kÃ¤riasema</name>
      <address>
        <city>Mannnerheiminaukio 1 B 2 Floor</city>
        <state>Helsinki</state>
        <zip>0100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Finnish Special Neurology Center Ltd.</name>
      <address>
        <city>Brahenkatu 11 D,</city>
        <state>Turku</state>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suomen Terveystalo/ PÃ¤Ã¤nsÃ¤rkykeskus, Tampere</name>
      <address>
        <city>HÃ¤meenkatu 18, 6th fl., Tampere</city>
        <zip>33200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital, Neurology Department 799</name>
      <address>
        <city>Kiinanmyllynkatu 11- 14, Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HyvinkÃ¤Ã¤n sairaala</name>
      <address>
        <city>Neurologian poliklinikka, Sairaalankatu 1, HyvinkÃ¤Ã¤</city>
        <zip>05850</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU La Timone</name>
      <address>
        <city>Service Neurologie, Boulevard Jean Moulin, Marsielle Cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Giessen</city>
        <zip>35385</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Munchen</city>
        <zip>80331</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Munchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Munster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Seesen/Harz</city>
        <zip>38723</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Stuttgart</city>
        <zip>70191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Tubingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Wurzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Athens Naval Hospital, Neurology Department</name>
      <address>
        <city>Athens</city>
        <zip>11521</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Department Athens General Hospital, G. Gennimatas</name>
      <address>
        <city>Mesogeion 154 Ave., Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st IKA Papadimitriou Neurology Dept</name>
      <address>
        <city>Terma Zaimi, Melissia-Athens</city>
        <zip>15127</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Thessaloniki &quot;AHEPA&quot;, B' University Department of Neurology</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <zip>78306</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sieff Medical Center</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba - Medical Center</name>
      <address>
        <city>Tel Hashomer, Ramat-Gan,</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaunas University Hospital Department of Neurology</name>
      <address>
        <city>Eiveniu 2, Kaunas</city>
        <zip>LY-50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis VU</name>
      <address>
        <city>De Boelelaan 1118</city>
        <state>Amsterdam</state>
        <zip>1081</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Postbus 2500</city>
        <state>Nieuwegein</state>
        <zip>3430 EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiple Clerosis Center Nijmegen</name>
      <address>
        <city>Heiweg 97</city>
        <state>Nyimegen</state>
        <zip>6533</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Dr. Molewaterplein 40</city>
        <state>Rotterdam</state>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Elisabeth Ziekenhuis</name>
      <address>
        <city>Hilvarenbeekse Weg 60</city>
        <state>Tilburg</state>
        <zip>5022</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maaslandziekenhuis Sittard</name>
      <address>
        <city>Walramstraat 23, BK Sittard</city>
        <zip>6131</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny</name>
      <address>
        <city>Klinika Neurologii, Ul. Marii SkÅodowskiej-Curie 24 A</city>
        <state>Bialystok</state>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niezalezny Zespol Opieki Zdrowotnej Kendron</name>
      <address>
        <city>Ul. Swietego Mikolaja 1/8</city>
        <state>Bialystok</state>
        <zip>15-420</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddzial Neurologiczny i Leczenia Udarow</name>
      <address>
        <city>Mozgu, Nowe Ogrody 1/6</city>
        <state>GdaÅsk</state>
        <zip>80-803</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Neurologii Slaskiej Akademii Medycznej</name>
      <address>
        <city>ul. Medykow 14</city>
        <state>Katowice</state>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Med. Sci. Poznan, Katedra i Klinika Neurologii,</name>
      <address>
        <city>Department of Neurology, ul. Przybyszewskiego 49</city>
        <state>Poznan</state>
        <zip>60-355</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSK MSWiA Hospital</name>
      <address>
        <city>Department of Neurology, WoÅoska 137</city>
        <state>Warsaw</state>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jadwiga Kruszewska-Ozimska, Instytut Psychiatrii i Neurologii</name>
      <address>
        <city>II Klinika Neurologii, ul. Sobieskiego 1/9</city>
        <state>Warsaw</state>
        <zip>02-957</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny, Klinika Neurologii</name>
      <address>
        <city>MSWiAw Warszawie, Woloska 137</city>
        <state>Warszawa</state>
        <zip>00-909</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Neurologii Centralny Szpital Kliniczny AM w Warszawie</name>
      <address>
        <city>ul. Banacha 1A</city>
        <state>Warszawa</state>
        <zip>01-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Lodz</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interregional Clinical Diagnistic Center, Neurology Department</name>
      <address>
        <city>Kazan</city>
        <zip>420111</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital of Medical Center of Administration of President of Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>121356</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Regional Research Clinical Institue</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GUZ &quot;Central Medical Sanitary Department #122 of Federal Medical-Biological agency&quot;, Neurology department</name>
      <address>
        <city>St-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy, Neurology Department</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>II. NeurologickÃ¡ klinika FakultnÃ¡ nemocnica s poliklinikou Bratislava pracovisko KramÃ¡re</name>
      <address>
        <city>LimbovÃ¡ 5</city>
        <state>Bratislava</state>
        <zip>833 05</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeurologickÃ¡ klinika, MartinskÃ¡ fakultnÃ¡ nemocnica</name>
      <address>
        <city>KollÃ¡rova 2, Martin</city>
        <zip>03659</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I. NeurologickÃ¡ klinika, FakultnÃ¡ nemocnica s poliklinikou Bratislava pracovisko StarÃ© mesto</name>
      <address>
        <city>Mickiewiczova 13, Bratislava</city>
        <zip>813 69</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeurologickÃ© oddelenie, Nemocnica s poliklinikou Å½ilina</name>
      <address>
        <city>ul.V. Spanyola 43, Å½ilina</city>
        <zip>012 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umhlanga Hospital</name>
      <address>
        <city>Umhlanga</city>
        <state>KZN</state>
        <zip>4319</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Neurology, Groote Schuur Hospital</name>
      <address>
        <city>E 8-74, Groote Schuur Hospital, Observatory Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Neurologist (Morningside Medi-Clinic), Suite C, Block C, Rochester Place</name>
      <address>
        <city>Sandton</city>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MS Centrum</name>
      <address>
        <city>Forskningsenhet, SU/Ãstra CKÃ plan 0</city>
        <state>Gothenburg</state>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital Huddinge</name>
      <address>
        <city>Department Of Neurology R54, Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital, Department of Medicine</name>
      <address>
        <city>Neuroimmunology unit, CMM L8:04, Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Basel, Policlinic</name>
      <address>
        <city>Neurology-Neurosurgical, Petersgraben 4</city>
        <state>Basel</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier, Universitaire Vaudois Policlinique de Neurologie</name>
      <address>
        <city>Rue du Bugnon</city>
        <state>Lausanne</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsSpital ZÃ¼rich, Neurologische Klinik</name>
      <address>
        <city>Frauenklinikstr. 26, Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universiti Hospitals</name>
      <address>
        <city>Department of Neurology</city>
        <state>Ankara</state>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gazi University</name>
      <address>
        <city>Medical Faculty Neurology Department</city>
        <state>Besevler Ankara</state>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EGE University</name>
      <address>
        <city>Medical Faculty Hospital Neurolgy Department</city>
        <state>Bornova Izmir</state>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University, Istanbul Faculty of Medicine</name>
      <address>
        <city>Departement of Neurology</city>
        <state>Capa Istanbul</state>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University, Cerrahpasa School of Medicine</name>
      <address>
        <city>Department of Neurology</city>
        <state>Cerrahpasa Istanbul</state>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gaziantep University School of Medicine</name>
      <address>
        <city>Neurology Department</city>
        <state>Gaziantep</state>
        <zip>27070</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uludag University Faculty of Medche</name>
      <address>
        <city>Tip Fakultesi, Noroloji ABD</city>
        <state>GÃ¶rÃ¼kle / Bursa</state>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tepecik Training and Research</name>
      <address>
        <city>Hospital Neurology Service, 35120 Gaziler Cad. Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokuz University Medical Faculty, Neurology Department</name>
      <address>
        <city>Inciralti, Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bakirkoy Ruh ve Sinir Hastaliklari Hastanesi</name>
      <address>
        <city>Istanbul</city>
        <zip>34147</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mersin Universitesi Tip Fakultesi Hastanesi</name>
      <address>
        <city>Noroloji ABD, Mersin</city>
        <zip>33079</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>T.C. Saglik Bakanligi Goztepe Egitim ve Arastirma Hastanesi</name>
      <address>
        <city>Noroloji Klinigi, GÃ¶ztepe Istanbul</city>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital, Trials office Academie Neuroscience Center</name>
      <address>
        <city>P041 Institute of Psychiatry, Denmark Hill</city>
        <state>London</state>
        <zip>SES 8AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queens Medical Centre</name>
      <address>
        <city>Division of Clinical Neurology Medical School</city>
        <state>Nottingham</state>
        <zip>NG7 24H</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Glossop Road</city>
        <state>Sheffield</state>
        <zip>S102JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. George's Hospital, Neurology Dept. Atkinson Morley Wing</name>
      <address>
        <city>Backshaw Road, London</city>
        <zip>Tooting London SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frenchay Hospital, Department of Neurology</name>
      <address>
        <city>Beckspool Road, Bristol</city>
        <zip>BS16 1LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Queen Victoria Road, Newcastle-upon-Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <link>
    <url>http://www.msclinicaltrials.com</url>
    <description>Fingolimod clinical trials information website</description>
  </link>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2006</study_first_submitted>
  <study_first_submitted_qc>February 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2006</study_first_posted>
  <results_first_submitted>January 4, 2011</results_first_submitted>
  <results_first_submitted_qc>February 22, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 16, 2011</results_first_posted>
  <last_update_submitted>April 9, 2012</last_update_submitted>
  <last_update_submitted_qc>April 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>FTY720</keyword>
  <keyword>Fingolimod</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fingolimod Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fingolimod 1.25 mg</title>
          <description>Patients self-administered fingolimod 1.25 mg capsules orally once daily.</description>
        </group>
        <group group_id="P2">
          <title>Fingolimod 0.5 mg</title>
          <description>Patients self-administered fingolimod 0.5 mg capsules orally once daily.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Patients self-administered a fingolimod placebo capsule orally once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="429"/>
                <participants group_id="P2" count="425"/>
                <participants group_id="P3" count="418"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="332">296 completed on study drug, 35 completed off study drug.</participants>
                <participants group_id="P2" count="369">345 completed on study drug, 24 completed off study drug.</participants>
                <participants group_id="P3" count="332">303 completed on study drug, 29 completed off study drug.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="86"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory value(s)</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure result(s)</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fingolimod 1.25 mg</title>
          <description>Patients self-administered fingolimod 1.25 mg capsules orally once daily.</description>
        </group>
        <group group_id="B2">
          <title>Fingolimod 0.5 mg</title>
          <description>Patients self-administered fingolimod 0.5 mg capsules orally once daily.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Patients self-administered a fingolimod placebo capsule orally once daily.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="429"/>
            <count group_id="B2" value="425"/>
            <count group_id="B3" value="418"/>
            <count group_id="B4" value="1272"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.4" spread="8.91"/>
                    <measurement group_id="B2" value="36.6" spread="8.77"/>
                    <measurement group_id="B3" value="37.2" spread="8.60"/>
                    <measurement group_id="B4" value="37.1" spread="8.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 -30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>31-40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="162"/>
                    <measurement group_id="B3" value="165"/>
                    <measurement group_id="B4" value="474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>41-55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="156"/>
                    <measurement group_id="B4" value="473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="295"/>
                    <measurement group_id="B2" value="296"/>
                    <measurement group_id="B3" value="298"/>
                    <measurement group_id="B4" value="889"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of multiple sclerosis since first symptoms</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.4" spread="6.86" lower_limit="0" upper_limit="37"/>
                    <measurement group_id="B2" value="8.0" spread="6.60" lower_limit="0" upper_limit="35"/>
                    <measurement group_id="B3" value="8.1" spread="6.35" lower_limit="0" upper_limit="32"/>
                    <measurement group_id="B4" value="8.2" spread="6.60" lower_limit="0" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of relapses in last 2 years</title>
          <units>relapses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.5" spread="0.81" lower_limit="1" upper_limit="10"/>
                    <measurement group_id="B2" value="1.5" spread="0.76" lower_limit="1" upper_limit="11"/>
                    <measurement group_id="B3" value="1.4" spread="0.73" lower_limit="1" upper_limit="10"/>
                    <measurement group_id="B4" value="1.5" spread="0.77" lower_limit="1" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Expanded Disability Status Scale (EDSS)</title>
          <description>The EDSS is a scale for assessing disability in 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel &amp; bladder, cerebral, other functions). Based on scores in these 8 functional systems, an overall score ranging from 0 (normal) to 10 (death due to MS) is assigned. Patients with EDSS scores of 0.0 to 4.5 are fully ambulatory; patients with EDSS scores of 5.0 to 9.5 have impaired ambulation. EDSS was assessed by an evaluating physician at each site.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.41" spread="1.36" lower_limit="0" upper_limit="5.5"/>
                    <measurement group_id="B2" value="2.30" spread="1.29" lower_limit="0" upper_limit="5.5"/>
                    <measurement group_id="B3" value="2.49" spread="1.29" lower_limit="0" upper_limit="5.5"/>
                    <measurement group_id="B4" value="2.40" spread="1.32" lower_limit="0" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Estimated Annualized Aggregate Relapse Rate (ARR)</title>
        <description>The ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group calculated as the total number of confirmed relapses divided by the total number of days on study, multiplied by 365.25.</description>
        <time_frame>Baseline to end of study (Month 24)</time_frame>
        <population>This analysis was conducted using the Intent-to-treat (ITT) population which includes all patients who were randomized and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod 1.25 mg</title>
            <description>Patients self-administered fingolimod 1.25 mg capsules orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod 0.5 mg</title>
            <description>Patients self-administered fingolimod 0.5 mg capsules orally once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients self-administered a fingolimod placebo capsule orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Annualized Aggregate Relapse Rate (ARR)</title>
          <description>The ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group calculated as the total number of confirmed relapses divided by the total number of days on study, multiplied by 365.25.</description>
          <population>This analysis was conducted using the Intent-to-treat (ITT) population which includes all patients who were randomized and received at least one dose of study drug.</population>
          <units>Relapses per year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="425"/>
                <count group_id="O3" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" lower_limit="0.13" upper_limit="0.19"/>
                    <measurement group_id="O2" value="0.18" lower_limit="0.15" upper_limit="0.22"/>
                    <measurement group_id="O3" value="0.40" lower_limit="0.34" upper_limit="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Free of Disability Progression at Month 24 Assessed With the Expanded Disability Status Scale (EDSS)</title>
        <description>EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the following: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. A 3-month confirmed disability progression required onset EDSS, 3-month confirming EDSS, and all EDSS in between to meet the disability progression criteria. Percent of free of disability progression was calculated using the Kaplan Meier method.</description>
        <time_frame>Baseline to end of study (Month 24)</time_frame>
        <population>Intent-to-treat population (ITT): All patients who were randomized and received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod 1.25 mg</title>
            <description>Patients self-administered fingolimod 1.25 mg capsules orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod 0.5 mg</title>
            <description>Patients self-administered fingolimod 0.5 mg capsules orally once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients self-administered a fingolimod placebo capsule orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Free of Disability Progression at Month 24 Assessed With the Expanded Disability Status Scale (EDSS)</title>
          <description>EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the following: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. A 3-month confirmed disability progression required onset EDSS, 3-month confirming EDSS, and all EDSS in between to meet the disability progression criteria. Percent of free of disability progression was calculated using the Kaplan Meier method.</description>
          <population>Intent-to-treat population (ITT): All patients who were randomized and received at least one dose of study medication.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="425"/>
                <count group_id="O3" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.4" spread="1.87" lower_limit="79.7" upper_limit="87.1"/>
                    <measurement group_id="O2" value="82.3" spread="1.89" lower_limit="78.6" upper_limit="86.1"/>
                    <measurement group_id="O3" value="75.9" spread="2.17" lower_limit="71.7" upper_limit="80.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of New or Newly Enlarged T2 Lesions at Month 24 in Comparison With Baseline</title>
        <description>The number of new or newly enlarged T2 lesions at Month 24 in comparison to baseline was assessed with T2-weighted magnetic resonance image (MRI) scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2-weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.</description>
        <time_frame>Baseline to end of study (Month 24)</time_frame>
        <population>Intent-to-treat population (ITT): All patients who were randomized and received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod 1.25 mg</title>
            <description>Patients self-administered fingolimod 1.25 mg capsules orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod 0.5 mg</title>
            <description>Patients self-administered fingolimod 0.5 mg capsules orally once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients self-administered a fingolimod placebo capsule orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of New or Newly Enlarged T2 Lesions at Month 24 in Comparison With Baseline</title>
          <description>The number of new or newly enlarged T2 lesions at Month 24 in comparison to baseline was assessed with T2-weighted magnetic resonance image (MRI) scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2-weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.</description>
          <population>Intent-to-treat population (ITT): All patients who were randomized and received at least one dose of study medication.</population>
          <units>T2 lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="425"/>
                <count group_id="O3" value="418"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>patients with non-missing values</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="337"/>
                <count group_id="O2" value="370"/>
                <count group_id="O3" value="339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="5.52"/>
                    <measurement group_id="O2" value="2.5" spread="7.19"/>
                    <measurement group_id="O3" value="9.8" spread="13.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 Months</time_frame>
      <desc>Adverse events are reported based on the safety population. The safety population consists of all patients who received at least 1 dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fingolimod 1.25 mg</title>
          <description>Patients self-administered fingolimod 1.25 mg capsules orally once daily.</description>
        </group>
        <group group_id="E2">
          <title>Fingolimod 0.5 mg</title>
          <description>Patients self-administered fingolimod 0.5 mg capsules orally once daily.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Patients self-administered a fingolimod placebo capsule orally once daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Tachycardia paroxysmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Papilloedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Retinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Retinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Cytolytic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Abscess jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Dermo-hypodermitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Peritoneal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Peritonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Streptococcal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Fractured coccyx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Splenic injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Electrocardiogram PR prolongation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Electrocardiogram change</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Precancerous cells present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Red blood cell sedimentation rate increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Benign ovarian tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Brain neoplasm benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Migraine with aura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Monoplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Partial seizures with secondary generalisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Homicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Ovarian disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="346" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="355" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="323" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="115" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="115" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="96" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="425"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862 778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

